Peptide Radar

DSIP / Emideltide: evidence, claims & regulatory status

PR
Peptide Radar Research Desk
Independent evidence aggregator. Not a clinic, not medical advice. · Updated 2026-07-05 · How we grade evidence

Longevity & sleep PCAC: Pending vote (July 23-24, 2026)

A nonapeptide marketed for sleep and recovery. FDA noted safety/effectiveness gaps and available approved therapies, and proposed not adding it.

Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.

What it is

Delta Sleep-Inducing Peptide, a nonapeptide marketed for sleep, withdrawal and recovery. Not a clean first candidate for any established use.

Also known as: Delta Sleep-Inducing Peptide, Emideltide

Why people search it now

Sleep is a strong male-health need, driving interest despite weak data.

Claims by evidence grade

ClaimStrongest evidence
Sleep / insomniaR Regulatory only
Recovery / withdrawalD Cell / mechanistic

Regulatory status

FDA noted gaps in safety/effectiveness and the availability of approved therapies for the evaluated conditions; staff proposed not adding it.

Known risks & evidence gaps

Weak human data. Approved sleep therapies already exist and are better characterized.

FAQ

Is DSIP a proven sleep aid?

No. FDA noted safety/effectiveness gaps and proposed not adding it.

Official sources

Get the regulation & evidence watchlist

One email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.

Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.